Abstract
This technical disclosure describes methods of treating Alzheimer's disease by administering a combination of exactly two Potential Therapeutic Drugs (PTDs). PTDs are compounds that completed Phase III (or Phase II/III) clinical testing for Alzheimer's disease, were tolerated at the doses studied, but failed to demonstrate sufficient efficacy as monotherapies. Because Alzheimer's disease involves interacting pathological processes, including amyloid accumulation, neuroinflammation, tau pathology, and neurodegeneration, multi-target combinations may succeed where single agents failed. This disclosure identifies 20 PTD compounds spanning anti-amyloid, anti-neuroinflammation, anti-tau, neuroprotective, and symptomatic mechanism classes, and expressly sets forth all 190 unique pairwise combinations of them, together with variations in dosing ratio, route, schedule, formulation, and patient population. It is published to place every disclosed combination in the public domain as prior art.
Keywords: Alzheimer's disease; combination therapy; drug repurposing; discontinued drug candidates; amyloid; tau; neuroinflammation; defensive publication.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Recommended Citation
Zhang, Jianyi, "PAIRWISE COMBINATIONS OF LATE-STAGE DISCONTINUED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE", Technical Disclosure Commons, (November 09, 2026)
https://www.tdcommons.org/dpubs_series/12833